Aktienanalyse zu DaVita Inc (DVA)DVADaVita Inc

DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company's robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company's international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company's U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations. It operates in the Healthcare sector (SERVICES-MISC HEALTH & ALLIED SERVICES, NEC industry).

DaVita Inc is currently priced at $179.25, which is significantly below the analyst price target of $265 from Deutsche Bank, indicating potential upside. However, the stock has seen a 5-day change of only +0.31% and a year-to-date change of +56.54%, suggesting it may be nearing a peak. The RSI is at 53.606, indicating a neutral momentum, while the forward P/E is 9.95, suggesting the stock is reasonably valued. The main risk is the recent insider selling trend, with hedge funds increasing selling by 6939.07% over the last quarter, which could indicate a lack of confidence among large investors.

13 analysts cover DVA: 3 rate it Buy, 8 Hold and 2 Sell. The average price target is 162.50.